News
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings
Baird analyst Eric Coldwell maintained Quest Diagnostics with an Outperform rating and raised the price target from $191 to $194. Evercore ISI Group analyst Elizabeth Anderson maintained the stock with an In-Line rating and raised the price target from $175 to $180.
Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.
Truist analyst David MacDonald raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $182 and keeps a Hold rating on the ...
Quest Diagnostics Inc.'s stock fell 3.6% early Tuesday, after the company posted better-than-expected first-quarter earnings and backed its guidance, but said the early part of the quarter was ...
QUEST DIAGNOSTICS ($DGX) posted quarterly earnings results on Tuesday, April 22nd. The company reported earnings of $2.21 per share, beating estimates of $2.17 by $0. ...
Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $185 from $175 and keeps an Equal Weight rating on the shares. The ...
Quest Diagnostics Q1 2025 revenue rose to $2.65 billion with EPS of $2.21, exceeding expectations; full-year guidance for ...
Q1 2025 Management View Jim Davis, CEO, reported a 12% revenue growth in Q1 2025, attributed to contributions from acquisitions, large enterprise accounts, and the advanced diagnostics portfolio.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback